Clinical trials: Gram-Negative Bacterial Infections
Infections, Meningococcal
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults
The purpose of this study is to evaluate safety and immunogenicity of GSK Biologicals' meningococcal vaccine GSK134612 (MenACWY-TT) co-administered with Cervarix as compared to MenACWY-TT and Cervarix administered alone and the…
- Trial name
- NCT01755689
- Testing
- Meningococcal vaccine GSK134612, Cervarix®, Boostrix®
- Where
- 3 sites in Dominican Republic, Estonia and 1 more
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcal
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
The purpose of this study is to evaluate the immunogenicity and safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 to 5 months.
- Trial name
- NCT05252715
- Testing
- Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, Meningococcal A and C Polysaccharide Conjugate Vaccine
- Where
- 2 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Tetanus, Diphtheria
Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old
The aim of the study is to generate additional safety and immunogenicity data to support the registration of the product in Japan.
- Conditions
- Tetanus, Diphtheria, Pertussis
- Trial name
- NCT02089347
- Testing
- Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, Diphtheria and Tetanus toxoids adsorbed
- Where
- 19 sites in Japan
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Meningococcal
Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine
Meningococcal disease is mostly caused by N. meningitidis of serogroups A, B, C, W-135, Y. Meningococcal polysaccharide-conjugate vaccines have the advantage to induce a T-cell dependant immune response while the existing…
- Trial name
- NCT00356369
- Testing
- meningococcal ACWY (vaccine), Mencevax™ ACWY
- Where
- 3 sites in Philippines, Saudi Arabia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
E Coli Infections, Allogenic Transplant Patients
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC…
- Trial name
- NCT06938867
- Testing
- SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli
- Where
- 10 sites in United States
- Volunteers
- 66 people
- Sponsor
- SNIPR Biome Aps.
Diphtheria, Acellular Pertussis
Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants
This study aims to estimate the risk factors associated with pertussis/whopping cough infection among infants less than one year of age in a United States (U.S.) commercially insured population.
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Trial name
- NCT01890850
- Testing
- Retrospective database study using administrative claims data
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
The purpose of this study is to evaluate immunogenicity, safety and lot-to-lot consistency of LBVD in comparison to co-administration of Pentavalent vaccine and Poliomyelitis Vaccine (Inactivated) in separate injections at four…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT06947499
- Testing
- LBVD, Pentavalent vaccine and Inactivated Polio vaccine
- Where
- Philippines
- Volunteers
- 1,186 people, healthy volunteers welcome
- Sponsor
- LG Chem
Cystic Fibrosis
A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease.
- Trial name
- CARE-CF1 (NCT03000348)
- Testing
- Cysteamine
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 91 people
- Sponsor
- NovaBiotics Ltd.
Tetanus, Diphtheria
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose
The current trial will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083A vaccine when administered as a booster dose following priming in the first year of life with the same vaccine.
- Conditions
- Tetanus, Diphtheria, Haemophilus Influenzae Type b, Hepatitis B
- Trial name
- NCT01171989
- Testing
- GSK2202083A vaccine, Infanrix hexa™, Menjugate™
- Where
- 9 sites in Poland
- Volunteers
- 391 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF2 (NCT00104520)
- Testing
- AZLI 75 mg two times a day (BID)/three times a day (TID)
- Where
- 56 sites in United States
- Volunteers
- 211 people
- Sponsor
- Gilead Sciences
Meningitis, Meningococcal Infection
Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation
The purpose of this study is to assess the immunogenicity and safety of Menactra® vaccine given as a two-dose series in infants and toddlers.
- Trial name
- NCT01890759
- Testing
- Meningococcal Diphtheria Toxoid Vaccine
- Where
- 8 sites in India, Russia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Disease, Meningococcal Meningitis
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines
This study will evaluate safety, tolerability, and immunogenicity of a booster dose of a meningococcal vaccine formulation in adolescents.
- Trial name
- NCT01367158
- Testing
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Tdap
- Where
- 7 sites in Chile, Colombia and 1 more
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningitis, Meningococcal Disease
36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds
To further characterize the safety profile of Menactra vaccine and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.
- Trial name
- NCT00728260
- Testing
- None administered in this study
- Where
- United States
- Volunteers
- 1,421 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Gram-Negative Bacterial Infections
Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms
To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii, Enterobacter species, Klebsiella pneumoniae…
- Trial name
- NCT00079989
- Testing
- tigecycline
- Volunteers
- 115 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer